Literature DB >> 20379153

Safety signal dampens reception for mipomersen antisense.

Jim Kling.   

Abstract

Mesh：

Substances：

Year:  2010        PMID： 20379153     DOI： 10.1038/nbt0410-295

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Antisense--down, but not out.

Authors:  Carol Potera
Journal:  Nat Biotechnol       Date:  2007-04-30       Impact factor: 54.908

2.  Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial.

Authors:  Frederick J Raal; Raul D Santos; Dirk J Blom; A David Marais; Min-Ji Charng; William C Cromwell; Robin H Lachmann; Daniel Gaudet; Ju L Tan; Scott Chasan-Taber; Diane L Tribble; Joann D Flaim; Stanley T Crooke
Journal:  Lancet       Date:  2010-03-20       Impact factor: 79.321
  2 in total
  9 in total

1.  Biologics inch toward cholesterol-lowering market.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2012-04-10       Impact factor: 54.908

Review 2.  Silencing disease genes in the laboratory and the clinic.

Authors:  Jonathan K Watts; David R Corey
Journal:  J Pathol       Date:  2011-11-09       Impact factor: 7.996

3.  Antisense battles small molecule for slice of rare lipid disorder market.

Authors:  Gunjan Sinha
Journal:  Nat Biotechnol       Date:  2013-03       Impact factor: 54.908

4.  Compensatory and non-compensatory effects on protein expression following BCL-2 suppression by antisense oligonucleotides.

Authors:  Marvin Rubenstein; Courtney M P Hollowell; Patrick Guinan
Journal:  Med Oncol       Date:  2011-10-30       Impact factor: 3.064

Review 5.  Using Genome Sequence to Enable the Design of Medicines and Chemical Probes.

Authors:  Alicia J Angelbello; Jonathan L Chen; Jessica L Childs-Disney; Peiyuan Zhang; Zi-Fu Wang; Matthew D Disney
Journal:  Chem Rev       Date:  2018-01-11       Impact factor: 60.622

6.  In LNCaP cells enhanced expression of the androgen receptor compensates for Bcl-2 suppression by antisense oligonucleotides.

Authors:  Marvin Rubenstein; Courtney M P Hollowell; Patrick Guinan
Journal:  Ther Adv Urol       Date:  2011-04

7.  Blockage of the upregulation of voltage-gated sodium channel nav1.3 improves outcomes after experimental traumatic brain injury.

Authors:  Xian-Jian Huang; Wei-Ping Li; Yong Lin; Jun-Feng Feng; Feng Jia; Qing Mao; Ji-Yao Jiang
Journal:  J Neurotrauma       Date:  2013-12-06       Impact factor: 5.269

8.  RNA Interference-Guided Targeting of Hepatitis C Virus Replication with Antisense Locked Nucleic Acid-Based Oligonucleotides Containing 8-oxo-dG Modifications.

Authors:  Margit Mutso; Andrei Nikonov; Arno Pihlak; Eva Žusinaite; Liane Viru; Anastasia Selyutina; Tõnu Reintamm; Merike Kelve; Mart Saarma; Mati Karelson; Andres Merits
Journal:  PLoS One       Date:  2015-06-03       Impact factor: 3.240

9.  A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice.

Authors:  Haiyan Zhou; Narinder Janghra; Chalermchai Mitrpant; Rachel L Dickinson; Karen Anthony; Loren Price; Ian C Eperon; Stephen D Wilton; Jennifer Morgan; Francesco Muntoni
Journal:  Hum Gene Ther       Date:  2013-03-06       Impact factor: 5.695
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.